Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 10/20 | 0.65 |
| ▸ | SPR | P35270 | 1/20 | 0.50 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.45 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.45 |
| ▸ | RORC | P51449 | 2/20 | 0.44 |
| ▸ | NAMPT | P43490 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | APLNR | P35414 | 1/20 | 0.40 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1854468 | 0.79 | HSD11B1 (0.80) | HSD11B1PRMT5WDR77POLBHSD17B10 | |
| SCHEMBL1856520 | 0.78 | HSD11B1 (0.68) | HSD11B1SPRPRMT5WDR77RORC | |
| SCHEMBL1854822 | 0.76 | HSD11B1 (0.65) | HSD11B1SPRHSD17B10 | |
| SCHEMBL10568480 | 0.74 | POLB (0.67) | HSD11B1POLBHSD17B10P2RX1 | |
| SCHEMBL1856983 | 0.74 | HSD11B1 (0.63) | HSD11B1SPRPRMT5WDR77RORC | |
| SCHEMBL1862130 | 0.73 | HSD11B1 (0.65) | HSD11B1SPRRORCNAMPTPOLB | |
| SCHEMBL1860075 | 0.73 | HSD11B1 (0.61) | HSD11B1SPR | |
| SCHEMBL1855531 | 0.73 | HSD11B1 (0.61) | HSD11B1SPRRORC | |
| SCHEMBL1856848 | 0.73 | HSD11B1 (0.71) | HSD11B1POLBHSD17B10 | |
| SCHEMBL1856847 | 0.73 | HSD11B1 (0.71) | HSD11B1POLBHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7947834-B2 | Substituted quinoxalines, their preparation and their therapeutical use as 11βHSD1 modulators | SANOFI-AVENTIS (FR) | 2011-05-24 | — | — | US | disclosed |
| US-20090176775-A1 | DERIVATIVES OF UREAS OF PIPERIDINE OR PYRROLIDINE, THEIR PREPARATION AND THEIR THERAPEUTICAL USE | SANOFI-AVENTIS (FR) | 2009-07-09 | — | — | US | disclosed |
| EP-2044057-A2 | DERIVATIVES OF UREAS OF PIPERIDINE OR PYRROLIDINE, THEIR PREPARATION AND THEIR THERAPEUTICAL USE | Sanofi-Aventis (FR) | 2009-04-08 | — | — | EP | disclosed |
| WO-2008000950-A2 | DERIVATIVES OF UREAS OF PIPERIDINE OR PYRROLIDINE, THEIR PREPARATION AND THEIR THERAPEUTICAL USE | SANOFI-AVENTIS (FR) | 2008-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090176775-A1 | DERIVATIVES OF UREAS OF PIPERIDINE OR PYRROLIDINE, THEIR PREPARATION AND THEIR THERAPEUTICAL USE | HSD11B1, HSD3B1, ADH1C | HSD11B1 1/4885SPR 281/4885PRMT5 251/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.